In castration-resistant prostate cancer cells, treatment with NEO1132 or NEO2734 reduces H3K27ac at androgen receptor binding site-gained cell lineage and cancer-promoting gene loci, down-regulates their expression, induces castration-resistant prostate cancer cell growth inhibition and cell death in vitro, and abrogates tumors in mouse models 109. This evidence concerns the gene AR and prostate carcinoma.